Neurophet announced on Tuesday that it has signed a memorandum of understanding with the International Registry for Alzheimer’s Disease and Other Dementias Foundation (InRAD).

Through this agreement, Neurophet and InRAD will further expand their collaboration to establish global standards for clinical data related to Alzheimer's disease and dementia. Neurophet plans to seamlessly integrate AI-based brain imaging analysis technology into real clinical data environments, contributing to its wider adoption in clinical settings.

More specifically, the two sides will pursue the following objectives: advancing clinical workflows, including MRI (magnetic resonance imaging) and PET (positron emission tomography) image analysis; collecting and integrating clinical imaging data and quantitative data; validating the clinical utility of AI-based solutions; and developing joint research and educational programs.

This collaboration will utilize Neurophet's key solutions, including Neurophet AQUA, Neurophet AQUA AD, and Neurophet SCALE PET.

InRAD is an independent, international non-profit foundation headquartered in the Netherlands, supporting dementia researchers in utilizing data in a standardized manner to contribute to disease research and treatment improvement. It develops and operates Registry, Data Entry, and Collaborative platforms for Alzheimer's disease and dementia research. By collecting and utilizing real-world clinical data, it accelerates dementia research and supports decision-making by regulatory bodies and insurers.

In particular, InRAD is expanding its international influence based on a board composed of global scholars and clinical experts, including Professor Philip Scheltens, a dementia authority who established the “Scheltens Scale”—the world's first diagnostic criteria for distinguishing Alzheimer's disease in living patients using MRI.

“Collaborations like this play a crucial role in lowering barriers to collecting real-world data in clinical settings and supporting patient care,” Professor Scheltens said. “I am very pleased to announce this MOU.”

Neurophet Co-CEO Jake Been said, “Through this agreement, we expect to further enhance the global clinical applicability and reliability of Neurophet's AI-based brain imaging analysis solution, leveraging global dementia clinical data. We will contribute to enabling healthcare professionals and researchers worldwide to utilize standardized Alzheimer's disease data.”